MarketPulse

FDA-approved drugs

2 articles
BenzingaBenzinga··Vandana Singh

Biogen Acquires Apellis for $5.6B to Bolster Rare Disease Portfolio

Biogen acquires Apellis Pharmaceuticals for $5.6 billion in cash, gaining two FDA-approved therapies with $689M in 2025 projected sales and mid-to-high teens growth expectations.
APLSBIIBacquisitionbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Oncology Biotech Syndax Surges on $6.5M Investment Amid 629% Revenue Spike

Syndax Pharmaceuticals attracted $6.54M institutional investment as its approved cancer therapies generated $172.4M revenue, up 629% year-over-year, driving 80%+ stock surge.
SNDXrevenue growthcancer treatment